Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

Mise à jour : Il y a 4 ans
Référence : NCT02128958

Femme et Homme

Extrait

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.


Critère d'inclusion

  • Hepatocellular carcinoma


Liens